Clinical Trial Update: Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update notes that the Phase 2/3 study of Exisulind to prevent polyps in patients with familial adenomatous polyposis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Familial Adenomatous Polyposis
• Small Intestine Cancer

Drugs mentioned

• Exisulind (exisulind)

Snippet

Sponsor: University of Utah | Conditions: Colorectal Cancer, Small Intestine Cancer | Phase 2, Phase 3 | Status: WITHDRAWN